BACKGROUND: In 1999, the Canadian Hypertension Education Program (CHEP) was launched to develop and implement evidence-based hypertension guidelines. OBJECTIVES: To determine temporal trends in antihypertensive drug prescribing and physician visits for hypertension in Canada, and correlate these trends with CHEP recommendations. METHODS: Longitudinal drug data (Intercontinental Medical Statistics [IMS] CompuScript database; IMS Health Canada) were used to examine prescriptions over an 11-year period (1996 to 2006) for five major cardiovascular drug classes. The IMS Canadian Disease and Therapeutic Index database was used to determine trends in physician office visits for hypertension. RESULTS: Prescriptions for antihypertensive agents increased significantly over the 11-year period (4054% for angiotensin receptor blockers, 127% for thiazide diuretics, 108% for angiotensin-converting enzyme inhibitors, 87% for beta-blockers and 55% for calcium channel blockers). Time series analyses demonstrated increases in the growth rate for all drug classes, with the greatest annual change in prescriptions occurring during the 1999 to 2002 time period (except in angiotensin receptor blockers). An increase in prescriptions for fixed-dose combination products occurred, which was temporally related to the change in CHEP recommendations encouraging their use in 2001. The proportion of physician office visits for hypertension increased significantly from 4.9% in 1995 to 6.8% in 2005 (P<0.001). CONCLUSIONS: The largest increase in antihypertensive drug prescribing occurred in the period immediately following implementation of CHEP (1999 to 2002). Although prescribing rates are still increasing, the rate of change has decreased, suggesting that the treatment market for hypertension may be becoming saturated. The impact of these changes on blood pressure control and clinical outcomes remains to be determined.
BACKGROUND: In 1999, the Canadian Hypertension Education Program (CHEP) was launched to develop and implement evidence-based hypertension guidelines. OBJECTIVES: To determine temporal trends in antihypertensive drug prescribing and physician visits for hypertension in Canada, and correlate these trends with CHEP recommendations. METHODS: Longitudinal drug data (Intercontinental Medical Statistics [IMS] CompuScript database; IMS Health Canada) were used to examine prescriptions over an 11-year period (1996 to 2006) for five major cardiovascular drug classes. The IMS Canadian Disease and Therapeutic Index database was used to determine trends in physician office visits for hypertension. RESULTS: Prescriptions for antihypertensive agents increased significantly over the 11-year period (4054% for angiotensin receptor blockers, 127% for thiazide diuretics, 108% for angiotensin-converting enzyme inhibitors, 87% for beta-blockers and 55% for calcium channel blockers). Time series analyses demonstrated increases in the growth rate for all drug classes, with the greatest annual change in prescriptions occurring during the 1999 to 2002 time period (except in angiotensin receptor blockers). An increase in prescriptions for fixed-dose combination products occurred, which was temporally related to the change in CHEP recommendations encouraging their use in 2001. The proportion of physician office visits for hypertension increased significantly from 4.9% in 1995 to 6.8% in 2005 (P<0.001). CONCLUSIONS: The largest increase in antihypertensive drug prescribing occurred in the period immediately following implementation of CHEP (1999 to 2002). Although prescribing rates are still increasing, the rate of change has decreased, suggesting that the treatment market for hypertension may be becoming saturated. The impact of these changes on blood pressure control and clinical outcomes remains to be determined.
Authors: Norman R C Campbell; Finlay A McAlister; Rollin Brant; Mitch Levine; Denis Drouin; Ross Feldman; Robert Herman; Kelly Zarnke Journal: J Hypertens Date: 2003-08 Impact factor: 4.844
Authors: Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm Journal: Hypertension Date: 2003-11-24 Impact factor: 10.190
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng Journal: Lancet Date: 2004 Sep 11-17 Impact factor: 79.321
Authors: L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling Journal: Lancet Date: 1998-06-13 Impact factor: 79.321
Authors: B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl Journal: JAMA Date: 1995 Aug 23-30 Impact factor: 56.272
Authors: James B Byrd; Chan Zeng; Heather M Tavel; David J Magid; Patrick J O'Connor; Karen L Margolis; Joe V Selby; P Michael Ho Journal: Am Heart J Date: 2011-07-18 Impact factor: 4.749
Authors: Ann Thompson; Norm R Campbell; Lyne Cloutier; Jo-Anne Costello; Martin Dawes; John Hickey; Janusz Kaczorowski; Richard Z Lewanczuk; William Semchuk; Ross T Tsuyuki Journal: Can Fam Physician Date: 2008-12 Impact factor: 3.275
Authors: Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky Journal: Wien Klin Wochenschr Date: 2013-07-12 Impact factor: 1.704
Authors: Sheldon W Tobe; James A Stone; Melissa Brouwers; Onil Bhattacharyya; Kimberly M Walker; Martin Dawes; Jacques Genest; Steven Grover; Gordon Gubitz; David Lau; Andrew Pipe; Peter Selby; Mark S Tremblay; Darren E R Warburton; Richard Ward; Vincent Woo; Lawrence A Leiter; Peter P Liu Journal: CMAJ Date: 2011-09-12 Impact factor: 8.262
Authors: Cheri L McGowan; David N Proctor; Ian Swaine; Robert D Brook; Elizabeth A Jackson; Phillip D Levy Journal: Curr Hypertens Rep Date: 2017-06 Impact factor: 5.369